FDA Grants Profounda Orphan DD Approval for treatment of invasive candidiasis with Miltefosine
FDA Grants Profounda Orphan Drug Designation Approval for treatment of invasive candidiasis with Miltefosine - Invasive candidiasis is an...
ID WEEK in SAN DIEGO
The Profounda team had a booth at this years ID Week convention. Thanks to those that stopped by to learn more about Impavido
FDA Grants Profounda Inc. Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis
- GAE is a serious infection of the brain and spinal cord that typically occurs in persons with a compromised immune system. - Few...
AK and miltefosine
Three weeks after treatment with oral miltefosine offers promising hope for patients with AK. Miltefosine is not yet approved for AK but...
Five little-known diseases to watch out for in 2017
The phrase “emerging disease”, to describe an infectious disease that is new to humans or which is suddenly increasing its geographical...
IDSA, ASTMH release leishmaniasis guidelines following increase in US cases
An increase in leishmaniasis cases among travelers, immigrants and soldiers in the United States prompted the Infectious Diseases Society...
Deadly Parasitic Disease Finding Its Way to US Soil
Once thought to only be an issue for certain areas outside of the United States, cases of Leishmaniasis are on the rise as US soldiers...
Epidemiologic Correlates of Mortality among Symptomatic Visceral Leishmaniasis Cases: Findings from
More than 70% cases of visceral leishmaniasis (VL), a parasitic disease transmitted by sand flies, in India are reported from Bihar, a...
